Objective-The cognitive features and treatment of autism spectrum disorder (ASD) have been the subject of much debate in recent years. Therapeutic approaches to date have focused on skills acquisition, support tailored to the characteristics of ASD, and interventions in social cognitive functioning; there have been few reports describing interventions aimed at neurocognitive dysfunction. In this study we focus on impairment of executive functioning in ASD patients and investigate improvements in executive functioning and their generalization to social functioning. Method-The intervention adopted for this study was cognitive remediation therapy using the frontal/executive program (FEP). To investigate the effectiveness of FEP, 15 subjects who consented to participate in the study were randomly assigned to an intervention group or control group. FEP was administered to the intervention group for about 6 months. Both groups were evaluated using the same scales: BACS-J, WCST and CPT for cognitive assessment, SCoRS-J, GAF and LASMI for social functioning, and GSE for self-efficacy. Results-Both groups had lower scores for cognitive functioning than normal individuals at baseline. After completion of FEP, the intervention group showed improved performance on BACS-J for overall score, digit sequencing, verbal fluency, and Tower of London tasks. Improvements were also seen on SCoRS-J and LASMI scales of 4 social functioning. Conclusions-This was the first study to use FEP to focus on neurocognitive dysfunction in ASD patients. FEP is effective in improving impaired executive functioning in ASD patients and may also lead to improvements in some aspects of social functioning.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.